Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - NSCLC, metastatic

LBA60 - ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations

Date

18 Sep 2020

Session

Mini Oral - NSCLC, metastatic

Presenters

Mark Socinski

Citation

Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325

Authors

M.A. Socinski1, R. Cornelissen2, M.C. Garassino3, J. Clarke4, N. Tchekmedyian5, J. Molina6, J.W. Goldman7, G. Bhat8, F. Lebel9, X. Le10

Author affiliations

  • 1 Thoracic Oncology, AdventHealth Cancer Institute, 32803 - Orlando/US
  • 2 Medical Oncology, Erasmus University Medical Center, 3015 CE - Rotterdam/NL
  • 3 Medical Thoracic Oncology, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, 20133 - Milan/IT
  • 4 Medical Oncology, Duke University Medical Center, 27710 - Durham/US
  • 5 Medical Oncology, Pacific Shores Medical Group, 92618 - Irvine/US
  • 6 Medical Oncology, Mayo Clinic, 55905 - Rochester/US
  • 7 Medical Oncology, UCLA Hematology/Oncology Santa Monica, 90404 - Santa Monica/US
  • 8 Clinical Science, Spectrum Pharmaceuticals, 92618 - Irvine/US
  • 9 Research & Development, Spectrum Pharmaceuticals, 92618 - Irvine/US
  • 10 Department Of Thoracic Head And Neck Medical Oncology, MD Anderson Cancer Center, 77030 - Houston/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract LBA60

Background

Treatment of non-small cell lung cancer (NSCLC) with EGFR or HER2 exon 20 mutations is a serious unmet medical need. We are evaluating the efficacy and safety of poziotinib, a potent EGFR and HER2 exon 20 tyrosine kinase inhibitor (TKI), in a large, prospective multi-cohort study (N=603). Here, we report results from a cohort of previously treated patients with advanced NSCLC exon 20 insertion mutations (ZENITH20-2 N=90).

Methods

Patients enrolled in ZENITH20-2 had HER2 exon 20 insertion mutations per a CLIA certified (or equivalent) sequencing test. Poziotinib (16 mg) was administered orally QD, allowing dose interruptions/reductions for toxicity if needed. The primary endpoint was objective response rate (ORR), evaluated centrally by an independent image review committee using RECIST 1.1 with a 95% CI pre-specified lower bound of 17%. Secondary endpoints included disease control rate, duration of response, progression-free survival, and safety.

Results

In ZENITH20-2, 90 patients were enrolled with a median age of 60 years; 64% females, 66% non-smokers, 78% Caucasians, and 16% had concurrent clinically stable brain metastases at entry. Median number of prior therapies was 2 (range: 1-6), with 98% of patients having prior chemo/platinum-based therapy; 67% immunotherapy, including checkpoint inhibitors; and 28% HER2 therapy. The most common treatment-related Grade ≥3 AEs were rash (30%), diarrhea (26%), and mucosal inflammation (14%). ORR in 74 evaluable patients was 35.1% (95% CI: 24.4 – 47.1%) and 27.8% (95% CI: 18.9 – 38.2%) in all 90 patients (As-Treated Population). The 95% CI lower bound exceeded the protocol-specified threshold of 17%. Median DoR was 5.1 months (range: 1-12.3+ months) with 3 patients continuing on treatment. DCR was 70% and median PFS was 5.5 months (range: 0.03-13.1+ months). Responses were observed in most subgroups. Specifically, ORR was 38.7% in 31 patients with 3+ lines of therapy and 28.6% in 14 patients with CNS metastasis.

Conclusions

ZENITH20-2 met its ORR primary efficacy endpoint with durable responses and presented a manageable safety profile, typical of 2nd generation TKIs. Additional cohorts are enrolling to explore alternative dose levels and BID dosing.

Clinical trial identification

NCT03318939.

Editorial acknowledgement

Legal entity responsible for the study

Spectrum Pharmaceuticals.

Funding

Spectrum Pharmaceuticals.

Disclosure

M.A. Socinski: Research grant/Funding (institution): Spectrum Pharmaceuticals. R. Cornelissen: Research grant/Funding (institution): Spectrum Pharmaceuticals. M.C. Garassino: Research grant/Funding (institution): Spectrum Pharmaceuticals. J. Clarke: Research grant/Funding (institution): Spectrum Pharmaceuticals. N. Tchekmedyian: Research grant/Funding (institution): Spectrum Pharmaceuticals. J. Molina: Research grant/Funding (institution): Spectrum Pharmaceuticals. J.W. Goldman: Research grant/Funding (institution): Spectrum Pharmaceuticals. G. Bhat: Full/Part-time employment: Spectrum Pharmaceuticals. F. Lebel: Full/Part-time employment: Spectrum Pharmaceuticals. X. Le: Research grant/Funding (institution): Spectrum Pharmaceuticals.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings